Flex Pharma to Present at the Cantor Fitzgerald Healthcare Conference

BOSTON--(BUSINESS WIRE)-- Click to Tweet

Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the 2nd Annual Cantor Fitzgerald Healthcare Conference on Wednesday, July 13, 2016 at 11:45 a.m.

A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma’s website for 2 weeks following each presentation.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps. Flex Pharma was founded by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chair and CEO Christoph Westphal, M.D., Ph.D.

Visit www.TeamHOTSHOT.com for updates and to learn more about HOTSHOT™, the Company’s consumer product which is scientifically proven to prevent and treat muscle cramps.

HOTSHOT is a consumer product that is marketed to endurance athletes. HOTSHOT complements the Company’s drug development business and is not intended to diagnose, treat, cure or prevent any disease.

Follow Flex Pharma (@flexpharma) and HOTSHOTTM (@Team_HOTSHOT) on Twitter

View source version on businesswire.com: http://www.businesswire.com/news/home/20160706005272/en/

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications
[email protected]

Source: Flex Pharma, Inc.

You May Also Be Interested In

• Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
• Atlas Salt Inc. Announces Release with Conditions under the Environmental Protection Act for the Great Atlantic Salt Project
• TCTM Filed 2023 Annual Report on Form 20-F